Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

Slight body weight and systolic blood pressure reduction are important beneficial effects. Main adverse events of SGLT2 inhibitors are genital mycotic and urinary tract infections. Dapagliflozin ...

With studies showing potential for SGLT2 inhibitors in heart failure ... Brian Bird was also cautious about adverse effects, citing the issue of limb amputation and sharing concerns that this ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

or in the the APC or APPROVE trials. Controversy about the mechanisms of potential cardiovascular side effects of COX inhibitors and NSAIDs persists. Intriguingly, the sulfone COX2 inhibitors ...

Use of SGLT2 inhibitors was associated with a lower risk for rhabdomyolysis than DPP-4 inhibitors among statin users. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with a ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age. Cheng-Han Chen ...